›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing

Farah Champsi

Farah Chapmsi

farahchampsi

Managing Director

"This is a great time to build a company with breakthrough science and disease-modifying pharmaceuticals. I am excited to help visionary management teams execute their goals and build sustainable companies that will improve patients' lives. "

InterWest Team

Farah's bio

Portfolio
Company News

Farah's
Perspective

Farah's Buzz

Farah's video

Farah Champsi joined InterWest Partners as a managing director in May 2015. Since 2000, she has been a managing director at Alta Partners and played a key role in raising and managing over $1 billion in life sciences venture funds. She currently serves on the boards of Allakos and Kite Pharma. Farah is also responsible for Alta's investments in Cytokinetics, Intarcia, and Trevena. Previously, she led Alta's investments in Agensys (acquired by Astellas), Esperion (acquired by Pfizer), Excaliard (acquired by Pfizer), Orphan Medical (acquired by Jazz), Chimerix (IPO) and Portola (IPO). 

Prior to joining Alta in 2000, Farah was an investment banker for 13 years at Robertson Stephens & Company, where she focused on biotechnology and other life sciences companies. She was elected head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street.

In 2016 Farah was named as one of the top 15 women in biotech by FiercePharma, a leading publication in the biotech industry.

 Farah received an M.B.A. from Stanford University and a B.A. in Economics from Smith College. She serves on the board of UCSF Benioff Children’s Hospitals. 

When I began my career in biotech as an investment banker at Robertson Stephens in 1987 there were only a few dozen biotech companies. Today there are over a thousand companies. The biotech industry is undergoing unprecedented growth based on the success of numerous blockbuster products. This is a great time to build a company with breakthrough science and disease-modifying pharmaceuticals. I am excited to help visionary management teams execute their goals and build sustainable companies that will improve patients' lives.
Farah Chapmsi
Facebook Google+ Twitter Email LinkedIn Share